Association of MiR-155 Expression with Prognosis in Resected 
Stage III Non-small Cell Lung Cancer

Association of MiR-155 Expression with Prognosis in Resected 
Stage III Non-small Cell Lung Cancer

Background and objective Despite undergoing curative resection, the 5-year survival rate for stage III non-small cell lung cancer (NSCLC) patients is less than 25%. There is a need for biomarkers for prediction of survival and guiding individual therapy. MiR-155 is one of most commonly upregulated m...

Full description

Bibliographic Details
Main Authors: Yi GAO, Shengling FU, Wenyang JIANG, Binfeng LI, Yitao TIAN, Xiangning FU
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2014-05-01
Series:Chinese Journal of Lung Cancer
Subjects:
Lung neoplasms
MiR-155
Prognosis
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2014.05.10

Similar Items

Similar Items